Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 19

1.

Multicenter phase 2 trial of sirolimus for tuberous sclerosis: kidney angiomyolipomas and other tumors regress and VEGF- D levels decrease.

Dabora SL, Franz DN, Ashwal S, Sagalowsky A, DiMario FJ Jr, Miles D, Cutler D, Krueger D, Uppot RN, Rabenou R, Camposano S, Paolini J, Fennessy F, Lee N, Woodrum C, Manola J, Garber J, Thiele EA.

PLoS One. 2011;6(9):e23379. doi: 10.1371/journal.pone.0023379. Epub 2011 Sep 6.

2.

Rapamycin and its analogues (rapalogs) for Tuberous Sclerosis Complex-associated tumors: a systematic review on non-randomized studies using meta-analysis.

Sasongko TH, Ismail NF, Nik Abdul Malik NM, Zabidi-Hussin ZA.

Orphanet J Rare Dis. 2015 Aug 12;10:95. doi: 10.1186/s13023-015-0317-7. Review.

3.

Tuberous sclerosis complex-associated angiomyolipomas: focus on mTOR inhibition.

Budde K, Gaedeke J.

Am J Kidney Dis. 2012 Feb;59(2):276-83. doi: 10.1053/j.ajkd.2011.10.013. Epub 2011 Nov 29. Review.

PMID:
22130643
4.

Everolimus: an mTOR inhibitor for the treatment of tuberous sclerosis.

Franz DN.

Expert Rev Anticancer Ther. 2011 Aug;11(8):1181-92. doi: 10.1586/era.11.93. Review.

PMID:
21916571
5.

Differentiating the mTOR inhibitors everolimus and sirolimus in the treatment of tuberous sclerosis complex.

MacKeigan JP, Krueger DA.

Neuro Oncol. 2015 Dec;17(12):1550-9. doi: 10.1093/neuonc/nov152. Epub 2015 Aug 19. Review.

6.

Rapamycin and rapalogs for tuberous sclerosis complex.

Sasongko TH, Ismail NF, Zabidi-Hussin Z.

Cochrane Database Syst Rev. 2016 Jul 13;7:CD011272. doi: 10.1002/14651858.CD011272.pub2. Review.

PMID:
27409709
7.

Role of mTOR inhibition in the treatment of patients with renal angiomyolipomas.

Coombs EJ.

J Am Assoc Nurse Pract. 2013 Nov;25(11):588-96. doi: 10.1002/2327-6924.12081. Epub 2013 Oct 1. Review.

8.

Tuberous sclerosis and the kidney: from mesenchyme to epithelium, and beyond.

Henske EP.

Pediatr Nephrol. 2005 Jul;20(7):854-7. Epub 2005 Apr 26. Review.

PMID:
15856327
9.

Angiomyolipoma of kidney.

Eble JN.

Semin Diagn Pathol. 1998 Feb;15(1):21-40. Review.

PMID:
9503504
10.

Safety considerations of mammalian target of rapamycin inhibitors in tuberous sclerosis complex and renal transplantation.

Somers MJ, Paul E.

J Clin Pharmacol. 2015 Apr;55(4):368-76. doi: 10.1002/jcph.428. Epub 2014 Dec 30. Review.

PMID:
25402866
11.

Efficacy and safety of sirolimus for renal angiomyolipoma in patients with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis: a systematic review.

Peng ZF, Yang L, Wang TT, Han P, Liu ZH, Wei Q.

J Urol. 2014 Nov;192(5):1424-30. doi: 10.1016/j.juro.2014.04.096. Epub 2014 May 9. Review.

PMID:
24813310
12.

Mammalian target of rapamycin signaling and autophagy: roles in lymphangioleiomyomatosis therapy.

Yu J, Parkhitko AA, Henske EP.

Proc Am Thorac Soc. 2010 Feb;7(1):48-53. doi: 10.1513/pats.200909-104JS. Review.

13.

Nursing implications for the lifelong management of tuberous sclerosis complex.

Agricola K, Tudor C, Krueger D, Franz DN.

J Neurosci Nurs. 2013 Aug;45(4):226-42. doi: 10.1097/JNN.0b013e3182986146. Review.

PMID:
23812052
14.

Therapeutic targeting of mTOR in tuberous sclerosis.

Sampson JR.

Biochem Soc Trans. 2009 Feb;37(Pt 1):259-64. doi: 10.1042/BST0370259. Review.

PMID:
19143643
15.

Tuberous sclerosis complex: tumors and tumorigenesis.

Borkowska J, Schwartz RA, Kotulska K, Jozwiak S.

Int J Dermatol. 2011 Jan;50(1):13-20. doi: 10.1111/j.1365-4632.2010.04727.x. Review.

PMID:
21182496
16.

Evolving Strategies in the Treatment of Tuberous Sclerosis Complex-associated Angiomyolipomas (TSC-AML).

Kapoor A, Girard L, Lattouf JB, Pei Y, Rendon R, Card P, So A.

Urology. 2016 Mar;89:19-26. doi: 10.1016/j.urology.2015.12.009. Epub 2015 Dec 23. Review.

PMID:
26723178
17.

Renal angiomyolipomas, cysts, and cancer in tuberous sclerosis complex.

Neumann HP, Schwarzkopf G, Henske EP.

Semin Pediatr Neurol. 1998 Dec;5(4):269-75. Review.

PMID:
9874854
18.

Lymphangioleiomyomatosis: differential diagnosis and optimal management.

Xu KF, Lo BH.

Ther Clin Risk Manag. 2014 Aug 21;10:691-700. doi: 10.2147/TCRM.S50784. eCollection 2014. Review.

19.

Management of lymphangioleiomyomatosis.

Taveira-DaSilva AM, Moss J.

F1000Prime Rep. 2014 Dec 1;6:116. doi: 10.12703/P6-116. eCollection 2014. Review.

Supplemental Content

Support Center